Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPRIV in Pediatric Gaucher Disease Skeletal Development
NCT02528617Phase 4Withdrawn
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jul 2015
- Primary completion
- Oct 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of velaglucerase alfa in Gaucher disease type 1 (GD1), Gaucher disease type 3, sponsored by Baylor Scott & White Research Institute. Planned start Jul 2015; status: withdrawn.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)Gaucher disease type 3
Beyond the preview
Go deeper on NCT02528617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528617.